Immune drug shows promise against tough brain cancers
NCT ID NCT03718767
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if the immunotherapy drug nivolumab can stop or slow the growth of certain brain tumors (gliomas) that have IDH mutations. Researchers are especially interested in tumors with many genetic changes (hypermutator phenotype). The trial involves 62 adults who receive the drug intravenously every few weeks. The main goal is to see how long the tumor stays under control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Could cutting a wider margin around brain tumors extend survival?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?